Danaher beats Q2 profit estimates on strength in medical testing business
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/9/2026
- S&P 500 falls as AI worries hit software makers
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Harry and Meghan surprised by King Charles' letter on their status
- Citi initiates UiPath coverage with Buy rating and $23 target
- S&P 500 falls as AI worries hit software makers
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Danaher (DHR) PT Raised to $300 at Argus
July 24, 2024 8:57 AM EDTArgus analyst John Eade raised the price target on Danaher (NYSE: DHR) to $300.00 while maintaining a Buy rating.
The analyst comments "Our BUY rating on Danaher Corp. (NYSE: DHR) reflects our view that Danaher is well... More
Danaher (DHR) PT Raised to $275 at BofA Securities
July 24, 2024 5:24 AM EDTBofA Securities analyst Michael Ryskin raised the price target on Danaher (NYSE: DHR) to $275.00 (from $270.00) while maintaining a Neutral rating.
The analyst comments "Bioprocess market dynamics improved in the qtr, with most excess inventory having worked through the system and customers returning to normal... More
Danaher (DHR) PT Raised to $275 at Evercore ISI
July 23, 2024 12:02 PM EDTEvercore ISI analyst Vijay Kumar raised the price target on Danaher (NYSE: DHR) to $275.00 (from $260.00) while maintaining a Outperform rating.
The analyst comments "Thesis Update: Relative to the questions / fears heading into 1Q print, we thought DHR checked all the boxes and the results reaffirmed the normalization thesis. The 3 most recent data points in LST have been mixed / negative (RGEN mgmt. change, A Guide cut & last weeks SRT Guide cut), which made the DHR print topical. Overall results came in slight better vs Guide (- LSD core declines vs -MSD Guide), with the... More
